Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Randomized, Positive-Controlled, Open-label, Phase 3 Study of JK-1201I Compared with Topotecan in Patients with Relapsed Extensive Stage Small Cell Lung Cancer After Platinum-based First-line Chemotherapy

NCT06581380 is registered in ClinicalTrials.gov with JenKem Technology Co., Ltd. as lead sponsor.

NCT NCT06581380
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06581380 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Randomized, Positive-Controlled, Open-label, Phase 3 Study of JK-1201I Compared with Topotecan in Patients with Relapsed Extensive Stage Small Cell Lung Cancer After Platinum-based First-line Chemotherapy
Lead sponsor
JenKem Technology Co., Ltd.
Phase
Phase 3
Overall status
Not yet recruiting
Start date
September 16, 2024
Completion date
April 16, 2028
Enrollment
394 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

small cell lung cancer